A real-time PCR assay for quantification of parasite burden in murine models of leishmaniasis

Alejandro L. Antonia¹, Liuyang Wang¹, Dennis C Ko Corresp.¹, ²

¹ Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States
² Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States

Corresponding Author: Dennis C Ko
Email address: dennis.ko@duke.edu

Eukaryotic parasites in the genus Leishmania place approximately 350 million people per year at risk of disease. In addition to their global health significance, Leishmania spp. have served as an important model for delineating basic concepts in immunology such as T-helper cell polarization. There have been many qPCR-based assays reported for measuring parasite burden in humans and animals. However, these are largely optimized for use in clinical diagnosis and not specifically for animal models. This has led several of these assays to have suboptimal characteristics for use in animal models. For example, multi-copy number genes have been frequently used to increase sensitivity but are subject to greater plasticity within the genome and thus may confound effects of experimental manipulations in animal models. In this study, we developed a sybr-green based quantitative touchdown PCR assay for a highly conserved and single-copy putative RNA-binding protein, DRBD3. With primers that share greater than 90% sequence identity across all sequenced Leishmania spp., we demonstrate that this assay has a lower limit of detection of 100 fg of parasite DNA for L. major, L. donovani, L. venezuelensis, and L. panamensis. Using C57BL6/J mice, we used this assay to monitor parasite burden over 1 month of infection with two strains of L. major (Seidman and Friedlin), and L. venezuelensis. These characteristics rival the sensitivity of previously reported qPCR based methods of parasite quantitation while amplifying a stable, single copy gene. Use of this protocol in the future will lead to improved accuracy in animal based models and help to tease apart differences in biology of host-parasite interactions.
A Real-time PCR Assay for Quantification of Parasite Burden in Murine Models of Leishmaniasis

Authors:
Alejandro L. Antonia¹, Liuyang Wang¹, and Dennis C. Ko¹,²

Affiliations:
¹Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC 27710
²Division of Infectious Diseases, Department of Medicine, School of Medicine, Duke University, Durham, NC 27710

*To whom correspondence should be addressed: dennis.ko@duke.edu.
Abstract

Eukaryotic parasites in the genus *Leishmania* place approximately 350 million people per year at risk of disease. In addition to their global health significance, *Leishmania* spp. have served as an important model for delineating basic concepts in immunology such as T-helper cell polarization. There have been many qPCR-based assays reported for measuring parasite burden in humans and animals. However, these are largely optimized for use in clinical diagnosis and not specifically for animal models. This has led several of these assays to have suboptimal characteristics for use in animal models. For example, multi-copy number genes have been frequently used to increase sensitivity but are subject to greater plasticity within the genome and thus may confound effects of experimental manipulations in animal models. In this study, we developed a sybr-green based quantitative touchdown PCR assay for a highly conserved and single-copy putative RNA-binding protein, DRBD3. With primers that share greater than 90% sequence identity across all sequenced *Leishmania* spp., we demonstrate that this assay has a lower limit of detection of 100 fg of parasite DNA for *L. major*, *L. donovani*, *L. venezuelensis*, and *L. panamensis*. Using C57BL6/J mice, we used this assay to monitor parasite burden over 1 month of infection with two strains of *L. major* (Seidman and Friedlin), and *L. venezuelensis*. These characteristics rival the sensitivity of previously reported qPCR based methods of parasite quantitation while amplifying a stable, single copy gene. Use of this protocol in the future will lead to improved accuracy in animal based models and help to tease apart differences in biology of host-parasite interactions.
Introduction

Parasites in the genus *Leishmania* cause a spectrum of disease ranging from cutaneous (CL) to visceralizing (VL) disease and are frequently used in many experimental animal models. Up to 1.6 million people each year are infected with one of the forms of leishmaniasis (Alvar, Velez et al. 2012). This significant impact of disease resulted in an estimated 980,000 disability adjusted life years (DALYs) in 2016 (DALYs and Collaborators 2017). Further, these estimates are likely to significantly underestimate the burden caused by social and psychological stigmatization resulting from long term scarring (Bailey, Mondragon-Shem et al. 2017).

The outcome of *Leishmania* infection has been understood to depend on proper T-helper (T_h) cell polarization since the late 1980’s when it was shown that a T_h1 response promotes a healing immune response whereas a T_h2 response leads to progressive, non-healing disease (Scott, Natovitz et al. 1988, Heinzel, Sadick et al. 1989). Since then, animal models of leishmaniasis have continued to be used to characterize and understand many important aspects of the adaptive immune system. Despite these many advances in understanding immunologic concepts broadly, our understanding of the immune response to *Leishmania* spp. specifically is evolving to reflect greater nuances and complexities (Scott and Novais 2016). Further, current treatment options for leishmaniasis remain prolonged, expensive, have variable efficacy, and significant side effects presenting an urgent need for novel therapeutics (Ponte-Sucre, Gamarro et al. 2017). In order to investigate these effectively, it is paramount to have optimal laboratory techniques for assessing disease progression in animals accurately, reproducibly, and under a variety of experimental conditions.

Methods to monitor disease progression during *Leishmania* infection in cutaneous animal models have traditionally relied on measuring footpad swelling and using a limiting dilution assay.
(LDA) to quantify parasite burden (Sacks and Melby 2001). While LDA remains a reliable and sensitive technique for quantifying parasite burden, these assays are labor intensive, can be technically challenging, and take several weeks to obtain final results. Recent advances employing genetic manipulation of parasites to express live reporter molecules such as mCherry or luciferase allow advanced monitoring of the parasite in real time and over a long-time course; however, they require an additional layer of genetic manipulation on the parasite and often require expensive equipment for visualization (Roy, Dumas et al. 2000, Michel, Ferrua et al. 2011, Calvo-Alvarez, Guerrero et al. 2012). More recently developed protocols utilizing amplification of nucleic acids have been optimized for use in clinical diagnosis. Additionally, novel modifications to PCR based techniques, such as PCR-ELISA, hold significant promise in improving sensitivity and high throughput capacity of parasite detection (Kobets, Badalova et al. 2010). To meet the demands of a clinical diagnostic assay, such as high sensitivity and the ability to discriminate between \textit{Leishmania} spp., highly variable and multi-copy genes are most commonly used.

However, characteristics for clinical assays for \textit{Leishmania} detection are not necessarily ideal for use in experimental animal models. The ability to differentiate between different strains is not required when the infecting species is carefully controlled and delivered during experimental infection. Additionally, the use of multi-copy genes which are known to be present in regions of relative genomic plasticity, may change during the course of infection. This at best adds unpredictable variation to the assay and at worst confounds the observation by inducing a systematic change across only certain experimental conditions. For instance, a comparative genomic study suggested that the high degree of variability of gene copy number across \textit{Leishmania} spp. provides a potential mechanism to adapt to environmental change by altering gene expression (Rogers, Hilley et al. 2011). Subsequently experimental studies have confirmed
that *Leishmania* spp. regulate gene expression by altering gene copy number (Iantorno, Durrant et al. 2017), and that this process can lead to drug resistance (Laffitte, Leprohon et al. 2016). Finally, it is particularly important to select genes without an active role in disease, as any studies to further understand these or related pathways are subject to the risk of mutations or gene copy expansions rendering PCR at these sites unable to accurately compare across experimental conditions.

Recently, several efforts have been made to standardize lab protocols for detection and quantification of parasites from clinical isolates (Cruz, Millet et al. 2013, Leon, Munoz et al. 2017). However, similar comparative studies that emphasize assay traits optimized for experimental models of infection are lacking. Here we report a real-time quantitative PCR (qPCR) assay based on amplification of a single-copy, housekeeping *Leishmania* RNA binding protein (DRBD3) that is optimal for animal model studies. With touchdown cycling parameters, we were able to achieve a sensitivity of 100 fg per reaction which rivals most described PCR protocols for *Leishmania* quantification. Use of this assay in the future will facilitate studies elucidating mechanisms of immunity to *Leishmania* spp. and in monitoring efficacy of novel pharmaceutical interventions.

**Materials and Methods**

*Multisequence alignment and sequence Logo*

Traits of the DRBD3 gene were analyzed in TriTrypDB using the *L. major* Fd reference sequence (LmjF.04.1170) (Aslett, Aurrecoechea et al. 2010). The reference sequence used in NCBI Blast tool to identify homologous sequences was based on the *L. major* SD75.1 sequence in order to correspond with the parasite DNA used to validate the assay in this study. The 11 identified homologous genomic DNA sequences were downloaded and aligned using ClustalOmega (McWilliam, Li et al. 2013). The WebLogo tool was used to generate a sequence logo based on this alignment ([http://weblogo.berkeley.edu/](http://weblogo.berkeley.edu/)) (Crooks, Hon et al. 2004).
Primer design

Primers were designed using Primer-BLAST software (Ye, Coulouris et al. 2012). The gene for DRBD3 in the *Leishmania major* (MHOM/SN/74/Seidman) was input. Five pairs of primers with similar melt temperatures were initially tested. After amplification by conventional PCR, 3 of these primer pairs resulted in non-specific amplification as detected by ethidium bromide detection in a 1% agarose gel. Amplicon size was verified by separating the PCR product in a 1% agarose gel, visualizing the product by ethidium bromide staining, and comparing to 100bp DNA staining ladder (New England Bioscience, N3231S). Based on this initial screen, the primers reported in Figure 1B were then used to amplify wildtype *L. major* (MHOM/SN/74/Seidman) promastigote DNA as described below.

qPCR protocol for parasite quantification

After DNA isolation from each mouse tissue, 100ng of DNA was used per reaction on a plate with a standard curve of cultured promastigote DNA ranging from 1x10^7 fg – 100 fg per reaction. PCR reactions were set up in a final volume of 10 µl by adding 5µl of ITaq universal SYBR Green supermix (BioRad, Cat# 172-5121), 0.5µl of each primer (1µM concentration), and 100 ng genomic DNA per sample. Cycling parameters are described in Figure 1B. All PCR reactions were performed in triplicate. Samples were classified as having no *Leishmania*-specific amplification if melt temperature analysis revealed any products with a peak outside of the expected 84.7 ± 0.5°C in any of the triplicate reactions. Primer efficiency for each reaction was calculated using the formula \(10^{\left(\frac{m}{n}ight)} - 1\), where \(m\) is the slope from a plot of the C_t vs log(parasite DNA) with serial 10 fold dilutions ranging from 1x10^7 fg to 100 fg total DNA per reaction.

Total parasite DNA was calculated by first using the average C_t for each reaction to interpolate the fg of parasite DNA per 100 ng of total DNA relative to the standard curve included.
on each 96-well plate. DNA (fg per reaction) was then multiplied by the factor used to dilute each sample to 100 ng per PCR reaction in order to get total parasite DNA (fg) per tissue harvested.

Parasites and culture conditions

*Leishmania major* Seidman (Sd.) (MHOM/SN/74/Seidman), *Leishmania major* Friedlin (Fd.) (MHOM/IL/80/FN), *L. donovani* (MHOM/6D/62/1S), *L. venezuelensis* (MHOM/VE/80/H-16), and *L. panamensis* (MHOM/PA/94/PSC-1) were obtained from BEI Resources. Parasites were maintained in M199 media supplemented with 10% heat inactivated FBS and 0.2% hemin. Cultures were maintained by inoculating a new 10 mL culture with 200 µl of previous culture every 5 days. Infections in mice were performed with parasites that had been passaged less than 3 times *in vitro*.

Mouse infections

Wildtype C57BL6 mice from the Jackson Laboratory were maintained in the Duke Laboratory Animal Resource (DLAR) Breeding Core. All studies were approved under Duke University IACUC protocol A200-15-07. *L. major* (MHOM/SN/74/Seidman) parasites were prepared by washing 5 day old culture of promastigotes with Hanks Buffered Salt Solution (HBSS), counting by hemocytometer, and resuspending at 2 x 10^6 parasites per 50µl of HBSS. A 27G 1/2 mL syringe with permanently attached needle was used to inoculate the left hind footpad with 50µl of promastigote suspension. Mice were monitored at least twice weekly to track lesion development.

DNA was obtained using the Qiagen DNeasy Blood and Tissue Kit (Cat # 69504). In brief, tissue from the infected footpads and draining popliteal lymph node of each mouse was harvested. The contralateral footpad and lymph node was taken from each mouse to monitor for contamination. Tissue was placed into a clean 1.5mL microcentrifuge tube. To 180 µl of buffer
ATL and 20 µl of proteinase K was added to each tube prior to homogenizing the tissue with a bead beater and incubating samples at 37°C overnight before proceeding as indicated by manufacturer instructions. DNA quantity and quality was assessed using the Take3 application on a Synergy H1 BioTek plate reader prior to use in the qPCR assay described. 33 out of 35 uninfected footpads and non-draining lymph nodes included as negative controls, did not produce a leishmania specific product as determined by melt temperature analysis (84.7°C).

Results

qPCR assay design for the Leishmania RNA binding protein, DRBD3.

To design a qPCR assay with optimal characteristics for quantification of Leishmania parasite burden in experimental models, we first sought to identify a single copy gene essential to the parasite, but less likely to be actively involved in evasion of host defense. For this we chose putative Leishmania RNA binding protein (DRBD3), present in a single-copy on chromosome 4. The gene is classified as the double RNA binding domain 3 protein based on homology with DRBD3 in Trypanosoma brucei. Studies in T. brucei have identified a consensus binding sequence in the 3’UTR of mRNA transcripts and suggest that DRBD3 plays a role in modulating stress response (Fernandez-Moya, Garcia-Perez et al. 2012, Das, Bellofatto et al. 2015); however, there have been no functional studies of this protein in Leishmania spp. to date. The L. major entry for DRBD3 (LmjF.04.1170) on TriTrypDB indicates that the gene is constitutively expressed between parasite life-cycle stages, is not under immune pressure, and has minimal sequence variation between species (Aslett, Aurrecoechea et al. 2010). RNA-seq experiments in both L. major and L. amazonensis have demonstrated little to no change in expression of this gene between the promastigote and amastigote stage consistent with the characteristics of a constitutively expressed
housekeeping gene (Akopyants, Matlib et al. 2004, Leifso, Cohen-Freue et al. 2007, Aoki, Muxel et al. 2017). Additionally, there were no identified epitopes in the Immune Epitope Database (IEDB) corresponding to DRBD3 peptides, suggesting that it is not likely to be influenced by host immune pressure (Vita, Zarebski et al. 2010). To verify the homology of DRBD3 between *Leishmania* spp. we used the sequence from *L. major Sd.* as a reference, and used NCBI blast software to identify all related sequences. This blast search yielded 11 hits of protein coding genomic DNA within the genus *Leishmania*. Using ClustalOmega we then created a multisequence alignment, and in combination with NCBI Primer Blast tool designed primers over a highly-conserved region (Figure 1A). Both primers have complete conservation at 18 out of 20 nucleotides. This design allows using a single set of primers to PCR amplify a stable, housekeeping gene that is likely to be applicable across a broad range of *Leishmania* spp.

The assay was then validated with DNA from cultured *L. major Sd.* promastigotes. With touchdown PCR cycling parameters, one distinct product is visible by ethidium bromide staining, which corresponds with a single product by melt curve analysis at 84.7°C (Figure 1B-C). Based on a standard curve extending across six orders of magnitude from $1 \times 10^7$ fg – 100 fg of parasite DNA per reaction, the PCR had an average efficiency of 100.6% ($n = 6$) (Figure 1D). The assay can detect DNA above this, but is no longer within the linear range. Using this same assay, DNA from geographically and phenotypically diverse parasites (*L. major* Fd., *L. venezuelensis*, *L. panamensis*, and *L. donovani*) were then validated and found to have the same limit of quantification (100 fg) and comparable primer efficiency (Figure 1D). Of note, the *L. panamensis* sequence of DRBD3 has a mismatch at 2 out of 20 base pairs for each primer; however, this did not significantly impair the limit of quantification or primer efficiency. Therefore, we successfully
developed a novel touch-down based PCR assay for a single-copy, housekeeping gene in *Leishmania* spp. that is able to efficiently detect as low as 100 fg of parasite DNA per reaction.

**Validation of DRBD3 qPCR in vivo**

We then tested the assay’s ability to monitor parasite burden in the murine model of cutaneous leishmaniasis. Wildtype C57BL6 mice were inoculated subcutaneously with $2 \times 10^6$ cultured *L. major* Sd. promastigotes in the left hind footpad. At 1 day and 34 days post infection, DNA was isolated from the infected and uninfected footpads as well as the corresponding popliteal lymph nodes.

The assay was able to accurately monitor parasite burden over this course of infection. Representative amplification and melting temperature plots are shown in Figure 2A and B. In uninfected samples, nonspecific products were easily differentiated by a melting temperature outside of the expected $84.7 \pm 0.5^\circ$C. At 1 day post infection, 6 of 7 mice had low, yet detectable parasite burdens in the footpad, but only 2 out of 7 infected mice had detectable parasites in the draining lymph node. This is consistent with an expected delay in time for migration of *Leishmania* parasites to the draining lymph nodes. In both the draining lymph nodes and infected footpads, a significant increase in parasite burden was observed between 1 day and 34 days post infection, where all samples had leishmania specific amplification (Figure 2C).

Having established that the primers work *in vivo* to monitor *L. major* Sd. infection, we next validated the assay on the traditional reference strain of *L. major* Fd. and with a strain of *L. venezuelensis*. Measuring footpad thickness with calipers demonstrate that at 36 days post infection there are significantly larger lesions in the *L. major* Fd. infected mice. However, using the DRBD3 quantitative PCR method to quantify parasite burden revealed that the *L. venezuelensis*
infected lesions harbored more parasites despite the lower overall degree of inflammation and swelling at the site of the lesion (Figure 2D). The discordance is consistent with previous reports of *L. major* Fd. successfully clearing parasites, in contrast to infection with new world *Leishmania* spp. in the *leishmania* subgenus, such as *L. venezuelensis*, which results in smaller, chronic and non-healing lesions (Scott and Novais 2016). Therefore, this assay successfully monitors *Leishmania* spp. parasite burden in mouse models of cutaneous leishmaniasis.

Comparison of DRBD3 qPCR assay to other targets for quantification of *Leishmania* spp. infection in animal models

We compared the characteristics of the DRBD3 assay to other published qPCR assays. A wide variety of assays for *Leishmania* detection by PCR with diverse targets and characteristics have been described (Table 1); though, most have been optimized from the perspective of clinical diagnostics.

The most commonly used assays target multicopy genes. This produces advantages in regards to lower limits of detection and the potential to discriminate between species but come at the cost of uncertainty in gene stability at these plastic regions of the genome. 18s rRNA is present in up to 166 copies per parasite (Ivens, Peacock et al. 2005, Torres-Machorro, Hernandez et al. 2010), the internal transcribed spacer (ITS-1), found in between the small and large rRNA subunits between 40-200 (Cupolillo, Grimaldi Junior et al. 1995, Bensoussan, Nasereddin et al. 2006), minicircle kinetoplast DNA at up to 10,000 copies (Yurchenko, Merzlyak et al. 1999), and HSP70 at 5-7 (Folgueira, Canavate et al. 2007). These assays report limits of detection as low as 10 fg of parasite DNA per reaction. However, multicopy regions are often under significant change. For example, kDNA is particularly unstable in terms of copy number with reports of significant
variation between species, strains, lifecycle stages, and clinical isolates (Mary, Faraut et al. 2004, Weirather, Jeronimo et al. 2011, Jara, Adaui et al. 2013).

Single copy genes tend to be in more stable regions of the genome, but report higher limits of detection compared to multicopy gene assays and variable efficiencies between studies. Glucosephosphate isomerase (GPI), glucose 6 phosphate dehydrogenase (G6PD), Superoxide Dismutase 1 (SODB1) (Ghotloo, Haji Mollahoseini et al. 2015), Arginine Permease (AAP3) (Tellevik, Muller et al. 2014), and DNA polymerase alpha (Croan, Morrison et al. 1997) are all single copy genes for which *Leishmania* quantification by PCR has been described. The assay for GPI reports a higher limit of detection of 5.6 pg compared to other assays with limits of detection around 10-100 fg per reaction (Wortmann, Hochberg et al. 2005). Reported PCR efficiencies for the G6PD assays range from 50.4% to 95.7%. SODB1 and AAP3 described qPCR assays have competitive limits of detection and efficiencies (Tellevik, Muller et al. 2014, Ghotloo, Haji Mollahoseini et al. 2015); however, it has become increasingly apparent that both of these genes are important virulence factors. AAP3 is upregulated in response to arginine shortages in host macrophages, and SODB1 deficient *L. chagasi* parasites demonstrate impaired survival in host macrophages (Plewes, Barr et al. 2003, Castilho-Martins, Laranjeira da Silva et al. 2011, Goldman-Pinkovich, Balno et al. 2016, Muxel, Laranjeira-Silva et al. 2017). This raises concern about the reliability of the assays during experimental manipulation; particularly in light of *Leishmania* spp. regulating gene expression through copy number variation (Laffitte, Leprohon et al. 2016, Iantorno, Durrant et al. 2017).

Amplifying the gene target DNA polymerase alpha has similar characteristics to the DRBD3 assay. It is another example of single copy gene, which can be amplified at high efficiency with a limit of detection of 100 fg (Bretagne, Durand et al. 2001, Prina, Roux et al. 2007).
Therefore, for monitoring parasite burden accurately and precisely in animal models, the DRBD3 qPCR assay and the DNA polymerase alpha assay (Prina, Roux et al. 2007) fulfill the optimal characteristics.

**Discussion**

Animal models of leishmaniasis have proven to be valuable in understanding basic immunological concepts, and will be critical in future drug development programs to control this neglected tropical disease. The ability to accurately monitor parasite survival and replication in these models is paramount to properly understanding the biology of infection and monitoring the effectiveness of novel therapeutic interventions. The development of qPCR assays for parasite quantification has been widespread for clinical applications; however, there is no standardized qPCR protocol that is optimized specifically for use in animal models. Here we developed a novel touchdown qPCR assay of the single copy housekeeping gene, DRBD3, which has a limit of detection that rivals existing protocols while not being subject to changes in sequence or copy number that multicopy genes or genes required for virulence would be subject to.

Accurate measurement of parasite burden by qPCR is important for distinguishing between host and parasite mediated pathology. Disease progression of Leishmania animal models is traditionally done by a combination of measuring footpad thickness or directly measuring parasites through limiting dilution assays. Measuring the inflammation that results from infection by swelling at the site of inoculation is a valuable way to monitor severity of disease, but it is unable to distinguish between damage caused by overgrowth of the parasite and damage caused by dysregulated host derived inflammation. Studies showing that parasite growth does not perfectly correlate with lesion size, demonstrate the importance of distinguishing between parasite and host
mediated pathology (Hill, North et al. 1983, Bretagne, Durand et al. 2001). This is particularly relevant in the context of leishmaniasis where it is well documented that distinct disease manifestations are caused by both extremes of this spectrum (Scott and Novais 2016). Limiting dilution assays are useful for enumerating parasite burden, but are costly in terms of time and resources. Of note, the qPCR assay described here does require access to a real-time PCR thermocycler. However, given access to this equipment the protocol is significantly faster than the approximately 1 week required for parasites to grow using the LDA. After the initial overnight incubation used to isolate parasite DNA, using a qPCR approach to amplify parasite DNA allows determination of parasite burden in as little as 2-4 hours.

The single copy gene DRBD3 is highly conserved across *Leishmania* spp., and the primers used in this assay bind to a region of DNA over which 90% of the residues are completely conserved. However, it should be noted that the divergence of the 2 nucleotide positions occurs at the division between the *Leishmania leishmania* and *Leishmania viannia* subgenera. The primers reported here are 100% conserved within the *leishmania* subgenus. Within the *viannia* subgenus, the sequences are also 100% conserved, and are only altered at two sites between the two genera for each primer. We demonstrate that despite these two divergent sites, the described primers work with high efficiency for parasites in the *viannia* subgenus (*L. panamensis*, see Figure 1D). Further, the primers described here with optimal characteristics for parasite quantification in animal models could be adapted for use in developing iterations of PCR-based technology, such as PCR-ELISA (Kobets, Badalova et al. 2010), in order to further improve sensitivity and capacity of the assay. The DRBD3 qPCR assay for *Leishmania* quantification is therefore also likely to be a robust assay for labs in that validation of the assay one time will allow for use in a wide range of studies.
modeling parasites with distinct disease phenotypes and from diverse geographic and evolutionary backgrounds.

Conclusions

Careful consideration of protocols used to quantify parasite burden in experimental models of leishmaniasis is essential to fully understand host-parasite interactions and for assessing the efficacy of novel therapeutic interventions. The DRBD3 assay described here will allow for consistent detection of parasites in an unbiased manner with a low limit of detection, facilitating discoveries in basic science and improvements in leishmaniasis treatment.

References

Akopyants, N. S., R. S. Matlib, E. N. Bukanova, M. R. Smeds, B. H. Brownstein, G. D. Stormo and S. M. Beverley (2004). "Expression profiling using random genomic DNA microarrays identifies differentially expressed genes associated with three major developmental stages of the protozoan parasite Leishmania major." Mol Biochem Parasitol 136(1): 71-86.

Alvar, J., I. D. Velez, C. Bern, M. Herrero, P. Desjeux, J. Cano, J. Jannin, M. den Boer and W. H. O. L. C. Team (2012). "Leishmaniasis worldwide and global estimates of its incidence." PLoS One 7(5): e35671.

Aoki, J. I., S. M. Muxel, R. A. Zampieri, M. F. Laranjeira-Silva, K. E. Muller, A. H. Nerland and L. M. Floeter-Winter (2017). "RNA-seq transcriptional profiling of Leishmania amazonensis reveals an arginase-dependent gene expression regulation." PLoS Negl Trop Dis 11(10): e0006026.

Aslett, M., C. Aurrecoechea, M. Berriman, J. Brestelli, B. P. Brunk, M. Carrington, D. P. Depledge, S. Fischer, B. Gajria, X. Gao, M. J. Gardner, A. Gingle, G. Grant, O. S. Harb, M. Heiges, C. Hertz-Fowler, R. Houston, F. Innamorato, J. Iodice, J. C. Kissinger, E. Kraemer, W. Li, F. J. Logan, J. A. Miller, S. Mitra, P. J. Myler, V. Nayak, C. Pennington, I. Phan, D. F. Pinney, G. Ramasamy, M. B. Rogers, D. S. Roos, C. Ross, D. Sivam, D. F. Smith, G. Srinivasamoorthy, C. J. Stoeckert, Jr., S. Subramanian, R. Thibodeau, A. Tivey, C. Treatman, G. Velarde and H. Wang (2010). "TriTrypDB: a functional genomic resource for the Trypanosomatidae." Nucleic Acids Res 38(Database issue): D457-462.

Bailey, F., K. Mondragon-Shem, P. Hotez, J. A. Ruiz-Postigo, W. Al-Salem, A. Acosta-Serrano and D. H. Molyneux (2017). "A new perspective on cutaneous leishmaniasis-Implications for global prevalence and burden of disease estimates." PloS Negl Trop Dis 11(8): e0005739.

Bensoussan, E., A. Nasrshii, F. Jonas, L. F. Schnur and C. L. Jaffe (2006). "Comparison of PCR assays for diagnosis of cutaneous leishmaniasis." J Clin Microbiol 44(4): 1435-1439.
350 Bretagne, S., R. Durand, M. Olivi, A. F. Garin, A. Sulhainan, D. Rivollet, M. Vidaud and M. Deniau
351 (2001). "Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected
352 mice." Clin Diagn Lab Immunol 8(4): 828-831.
353
354 Calvo-Alvarez, E., N. A. Guerrero, R. Alvarez-Velilla, C. F. Prada, J. M. Requena, C. Punzon, M. A.
355 Llamas, F. J. Arevalo, L. Rivas, M. Fresno, Y. Perez-Pertejo, R. Balana-Fouce and R. M. Reguera
356 (2012). "Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for
357 both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis."
358 PLoS Negl Trop Dis 6(11): e1927.
359
360 Castilho-Martins, E. A., M. F. Laranjeira da Silva, M. G. dos Santos, S. M. Muxel and L. M. Floeter-
361 Winter (2011). "Axenic Leishmania amazonensis promastigotes sense both the external and
362 internal arginine pool distinctly regulating the two transporter-coding genes."
363 PLoS One 6(11): e27818.
364
365 Croan, D. G., D. A. Morrison and J. T. Ellis (1997). "Evolution of the genus Leishmania revealed by
366 comparison of DNA and RNA polymerase gene sequences." Mol Biochem Parasitol 89(2): 149-
367 159.
368
369 Crooks, G. E., G. Hon, J. M. Chandonia and S. E. Brenner (2004). "WebLogo: A sequence logo
370 generator." Genome Research 14(6): 1188-1190.
371
372 Cruz, I., A. Millet, E. Carrillo, M. Chenik, P. Salotra, S. Verma, N. Veland, M. Jara, V. Adaui, C.
373 Castrillon, J. Arevalo, J. Moreno and C. Canavate (2013). "An approach for interlaboratory
374 comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis." Exp
375 Parasitol 134(3): 281-289.
376
377 Cupolillo, E., G. Grimaldi Junior, H. Momen and S. M. Beverley (1995). "Intergenic region typing
378 (IRT): a rapid molecular approach to the characterization and evolution of Leishmania." Mol
379 Biochem Parasitol 73(1-2): 145-155.
380
381 DALYs, G. B. D. and H. Collaborators (2017). "Global, regional, and national disability-adjusted
382 life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195
383 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study
384 2016." Lancet 390(10100): 1260-1344.
385
386 Das, A., V. Bellofatto, J. Rosenfeld, M. Carrington, R. Romero-Zaliz, C. del Val and A. M. Estevez
387 (2015). "High throughput sequencing analysis of Trypanosoma brucei DRBD3/PTB1-bound
388 mRNAs." Mol Biochem Parasitol 199(1-2): 1-4.
389
390 Fernandez-Moya, S. M., A. Garcia-Perez, S. Kramer, M. Carrington and A. M. Estevez (2012).
391 "Alterations in DRBD3 ribonucleoprotein complexes in response to stress in Trypanosoma
392 brucei." PLoS One 7(11): e48870.
393
394 Folgueira, C., C. Canavate, C. Chicharro and J. M. Requena (2007). "Genomic organization and
395 expression of the HSP70 locus in New and Old World Leishmania species." Parasitology 134(Pt 3):
396 369-377.
397
398 Ghotloo, S., M. Haji Mollahoseini, A. Najafi and F. Yeganeh (2015). "Comparison of Parasite
399 Burden Using Real-Time Polymerase Chain Reaction Assay and Limiting Dilution Assay in
400 Leishmania major Infected Mouse." Iran J Parasitol 10(4): 571-576.
401
402 Goldman-Pinkovich, A., C. Balno, R. Strasser, M. Zeituni-Molad, K. Bendelak, D. Rentsch, M.
403 Ephros, M. Wiese, A. Jardim, P. J. Myler and D. Zilberstein (2016). "An Arginine Deprivation
404 Response Pathway Is Induced in Leishmania during Macrophage Invasion." PLoS Pathog 12(4):
405 e1005494.
Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman and R. M. Locksley (1989). "Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets." J Exp Med 169(1): 59-72.

Hill, J. O., R. J. North and F. M. Collins (1983). "Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis." Infect Immun 39(3): 1087-1094.

Iantorno, S. A., C. Durrant, A. Khan, M. J. Sanders, S. M. Beverley, W. C. Warren, M. Berriman, D. L. Sacks, J. A. Cotton and M. E. Grigg (2017). "Gene Expression in Leishmania Is Regulated Predominantly by Gene Dosage." MBio 8(5).

Ivens, A. C., C. S. Peacock, E. A. Worthey, L. Murphy, G. Aggarwal, M. Berriman, E. Sisk, M. A. Rajandream, E. Adlem, R. Aert, A. Anupama, Z. Apostolou, P. Attipoe, N. Bason, C. Bauser, A. Beck, S. M. Beverley, G. Blanchettin, K. Borzym, G. Bothe, C. V. Bruschi, M. Collins, E. Cadag, L. Ciarloni, C. Clayton, R. M. Coulson, A. Cronin, A. K. Cruz, R. M. Davies, J. De Gaudenzi, D. E. Dobson, A. Duesterhoeft, G. Fazelina, D. Harris, C. Hertz-Fowler, H. Hilbert, D. Horn, Y. Huang, S. Klages, A. Knights, M. Kube, N. Larke, L. Litvin, A. Lord, T. Louie, M. Marra, D. Masuy, K. Matthews, S. Michaeli, J. C. Mottram, S. Muller-Auer, H. Munden, S. Nelson, H. Norbertczak, K. Oliver, S. O'Neil, M. Pennyton, T. M. Pohl, C. Price, B. Purnelle, M. A. Quail, E. Rabinowitsch, R. Reinhardt, M. Rieger, J. Rinta, J. Robben, L. Robertson, J. C. Ruiz, S. Rutter, D. Saunders, M. Schafer, J. Schein, D. C. Schwartz, K. Seeger, A. Seyler, S. Sharp, H. Shin, D. Sivam, R. Squares, V. Tosato, C. Vogt, G. Volckaert, R. Wambutt, T. Warren, H. Wedler, J. Woodward, S. Zhou, W. Zimmermann, D. F. Smith, J. M. Blackwell, K. D. Stuart, B. Barrell and P. J. Myler (2005). "The genome of the kinetoplastid parasite, Leishmania major." Science 309(5733): 436-442.

Jara, M., V. Adaui, B. M. Valencia, D. Martinez, M. Alba, C. Castrillon, M. Cruz, I. Cruz, G. Van der Auwera, A. Llanos-Cuentas, J. C. Dujardin and J. Arevalo (2013). "Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters." J Clin Microbiol 51(6): 1826-1833.

Kobets, T., J. Badalova, I. Grekov, H. Havelkova, M. Svobodova and M. Lipoldova (2010). "Leishmania parasite detection and quantification using PCR-ELISA." Nat Protoc 5(6): 1074-1080.

Laffitte, M. N., P. Leprohon, B. Papadopoulou and M. Ouellette (2016). "Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance." F1000Res 5: 2350.

Leifso, K., G. Cohen-Freue, N. Dogra, A. Murray and W. R. McMaster (2007). "Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed." Mol Biochem Parasitol 152(1): 35-46.

Leon, C. M., M. Munoz, C. Hernandez, M. S. Ayala, C. Florez, A. Teheran, J. R. Cubides and J. D. Ramirez (2017). "Analytical Performance of Four Polymerase Chain Reaction (PCR) and Real Time PCR (qPCR) Assays for the Detection of Six Leishmania Species DNA in Colombia." Front Microbiol 8: 1907.

Mary, C., F. Faraut, L. Lascombe and H. Dumon (2004). "Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity." J Clin Microbiol 42(11): 5249-5255.

McWilliam, H., W. Z. Li, M. Uludag, S. Squizzato, Y. M. Park, N. Buso, A. P. Cowley and R. Lopez (2013). "Analysis Tool Web Services from the EMBL-EBI." Nucleic Acids Research 41(W1): W597-W600.
Michel, G., B. Ferrua, T. Lang, M. P. Maddugoda, P. Munro, C. Pomares, E. Lemichez and P. Marty (2011). "Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro." PLoS Negl Trop Dis 5(9): e1323.

Muxel, S. M., M. F. Laranjeira-Silva, R. A. Zampieri and L. M. Floeter-Winter (2017). "Leishmania (Leishmania) amazonensis induces macrophage miR-294 and miR-721 expression and modulates infection by targeting NOS2 and L-arginine metabolism." Sci Rep 7: 44141.

Plewes, K. A., S. D. Barr and L. Gedamu (2003). "Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival." Infect Immun 71(10): 5910-5920.

Ponte-Sucre, A., F. Gamarro, J. C. Dujardin, M. P. Barrett, R. Lopez-Velez, R. Garcia-Hernandez, A. W. Pountain, R. Mwenechanya and B. Papadopoulou (2017). "Drug resistance and treatment failure in leishmaniasis: A 21st century challenge." PLoS Negl Trop Dis 11(12): e0006052.

Prina, E., E. Roux, D. Mattei and G. Milon (2007). "Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR." Microbes Infect 9(11): 1307-1315.

Rogers, M. B., J. D. Hilley, N. J. Dickens, J. Wilkes, P. A. Bates, D. P. Depledge, D. Harris, Y. Her, P. Herzyk, H. Imamura, T. D. Otto, M. Sanders, K. Seeger, J. C. Dujardin, M. Berriman, D. F. Smith, C. Hertz-Fowler and J. C. Mottram (2011). "Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania." Genome Res 21(12): 2129-2142.

Roy, G., C. Dumas, D. Sereno, Y. Wu, A. K. Singh, M. J. Tremblay, M. Ouellette, M. Olivier and B. Papadopoulou (2000). "Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models." Mol Biochem Parasitol 110(2): 195-206.

Sacks, D. L. and P. C. Melby (2001). "Animal models for the analysis of immune responses to leishmaniasis." Curr Protoc Immunol Chapter 19: Unit 19 12.

Scott, P., P. Natovitz, R. L. Coffman, E. Pearce and A. Sher (1988). "CD4+ T cell subsets in experimental cutaneous leishmaniasis." Mem Inst Oswaldo Cruz 83 Suppl 1: 256-259.

Scott, P. and F. O. Novais (2016). "Cutaneous leishmaniasis: immune responses in protection and pathogenesis." Nat Rev Immunol 16(9): 581-592.

Scott, P. and F. O. Novais (2016). "Cutaneous leishmaniasis: immune responses in protection and pathogenesis." Nat Rev Immunol.

Tellevik, M. G., K. E. Muller, K. R. Lokken and A. H. Nerland (2014). "Detection of a broad range of Leishmania species and determination of parasite load of infected mouse by real-time PCR targeting the arginine permease gene AAP3." Acta Trop 137: 99-104.

Torres-Machorro, A. L., R. Hernandez, A. M. Cevallos and I. Lopez-Villasenor (2010). "Ribosomal RNA genes in eukaryotic microorganisms: witnesses of phylogeny?" FEMS Microbiol Rev 34(1): 47-86.

Vita, R., L. Zarebski, J. A. Greenbaum, H. Emami, I. Hoof, N. Salimi, R. Damle, A. Sette and B. Peters (2010). "The immune epitope database 2.0." Nucleic Acids Res 38(Database issue): D854-862.

Weirather, J. L., S. M. Jeronimo, S. Gautam, S. Sundar, M. Kang, M. A. Kurtz, R. Haque, A. Schriefer, S. Talhari, E. M. Carvalho, J. E. Donelson and M. E. Wilson (2011). "Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples." J Clin Microbiol 49(11): 3892-3904.
Wortmann, G., L. Hochberg, H. H. Houng, C. Sweeney, M. Zapor, N. Aronson, P. Weina and C. F. Ockenhouse (2005). "Rapid identification of Leishmania complexes by a real-time PCR assay." *Am J Trop Med Hyg* 73(6): 999-1004.

Ye, J., G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen and T. L. Madden (2012). "Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction." *BMC Bioinformatics* 13:134.

Yurchenko, V. Y., E. M. Merzlyak, A. A. Kolesnikov, L. P. Martinkina and Y. Y. Vengerov (1999). "Structure of Leishmania minicircle kinetoplast DNA classes." *J Clin Microbiol* 37(5): 1656-1657.
Figure 1

Primer design and optimization of DRBD3 based qPCR for parasite quantification.

A) Multisequence alignment based on 11 homologous sequences to \( L. \ major \) Sd. DRBD3 found using NCBI Blast B) Primer sequences and cycling parameters used. C) DRBD3 primers amplify a 140bp product specifically. Product visualized with ethidium bromide staining of a 1% agarose gel run and compared to New England BioLabs 100bp ladder. D) DRBD3 primers amplify diverse \textit{Leishmania} spp. A representative plot of \( C_t \) value vs log dilution of parasite burden is shown. The average primer efficiency (± standard error of the mean) is indicated in parentheses for the following species: \( L. \ major \) Seidman (n = 6), \( L. \ major \) Friedlin (n = 5), \( L. \ venezuelensis \) (n = 5), \( L. \ panamensis \) (n = 3), and \( L. \ donovani \) (n = 3).
Figure 2

DRBD3 primers are able to assess parasite burden from infected mouse tissue.

A-B) Representative amplification plots and melt curve analysis from the draining lymph nodes of mice at 34 days post infection. Parasites amplified from infected tissue had melting temperatures corresponding with the expected 84.7°C. DNA from uninfected tissue resulted in non-specific amplification at later cycles with melt temps outside of 84.7±0.5°C. Samples that generated any product outside of this range were classified as having no leishmania specific amplification. C) Quantification of total parasites in the draining popliteal lymph nodes and infected footpads at 1 and 34 days post infection with L. major Seidman (Sd.). At 1 day post infection, 5 lymph node samples had no leishmania specific amplification and are not plotted. All samples from 34 days post infection had detectable leishmania specific amplification. D) DRBD3 quantification provides insights to disease pathogenesis in L. major Freidlin (Fd.) and L. venezuelensis infections. Comparison of footpad thickness and parasite burden in the draining lymph nodes and infected footpads at 36 days post infection. 4 lymph node samples and 1 footpad samples had no leishmania specific amplification and are therefore not plotted. P- values calculated by parametric Students T-test.
Table 1 (on next page)

Comparison of described targets for qPCR based quantification of parasite burden in humans and animals.

(Bretagne, Durand et al. 2001, Nicolas, Prina et al. 2002, Bossolasco, Gaiera et al. 2003, Schonian, Nasereddin et al. 2003, Schulz, Mellenthin et al. 2003, Mary, Faraut et al. 2004, Wortmann, Hochberg et al. 2005, Prina, Roux et al. 2007, Castilho, Camargo et al. 2008, Deborggraeve, Laurent et al. 2008, van der Meide, Guerra et al. 2008, de Paiva Cavalcanti, Felinto de Brito et al. 2009, Bezerra-Vasconcelos, Melo et al. 2011, Jara, Adaui et al. 2013, Srivastava, Sweat et al. 2013, Toz, Culha et al. 2013, Tellevik, Muller et al. 2014, Ghotloo, Haji Mollahoseini et al. 2015, Zampieri, Laranjeira-Silva et al. 2016)
| Gene Target                                | Copy Number | Sybr/TaqMan? | Primer Efficiency | Limit of Quantification   | Amplified from Animal Sample | Citation(s)                                                                 |
|-------------------------------------------|-------------|-------------|-------------------|---------------------------|------------------------------|--------------------------------------------------------------------------------|
| Arginine Permease (AAP3)                  | 1           | TaqMan      | 1.051             | 10 fg                     | Mice                         | Tellevik (2013)                                                              |
| 18s rRNA                                  | 63-166      | TaqMan/Sybr | 0.831-0.942       | 10 fg                     | Humans; Sandflies             | Shulz (2003); van der Meide (2008); Bossolasco (2003); Prina (2007); Deborggraeve (2013); Bezerra-Vasconcelos (2011) |
| DNA Polymerase                            | 1           | TaqMan/Sybr | 0.934-0.9941      | 100 fg                    | Mice                         | Bretagne (2001); Prina (2007)                                               |
| DNA Polymerase                            | 1           | TaqMan/Sybr | 0.504-0.957       | 100 fg                    | Humans; Mice                  | Castilho (2008); Prina (2007)                                               |
| Glucose 6 Phosphate Dehydrogenase (G6PD)  | 1           | TaqMan/Sybr | 0.9237-0.9723     | 5.6 pg                    | Humans; Sandflies             | Zampieri (2016)                                                              |
| Glucosephosphosphate isomerase (GPI)      | 1           | TaqMan      | NR                | 20 gene copies per rxn    | Humans                       | Wortmann (2005)                                                             |
| Heat Shock Protein 70 (HSP70)             | 5-7         | SYTO9       | 0.79-1.05         | 10 fg                     | Humans; Mice; Sandflies       | Zampieri (2016)                                                              |
| Internal Transcribed Spacer (ITS1)        | 20-200      | TaqMan      | NR                | 0.2 parasites per sample  | Humans; Dogs                  | Toz (2013); Shonian (2003)                                                  |
| Kinetoplast Minicircle DNA (kDNA)         | 500-1000    | TaqMan/Sybr | 0.79-1.05         | 10 fg                     | Humans; Dogs; Hampsters; Mice; Sandflies | Nicolas (2002); Cavalcanti (2008); Francino (2006); Mary (2004); Jara (2013); Srivastava (2013); Bezerra-Vasconcelos (2011) |
| RNA Binding Protein (DRBD3)               | 1           | Sybr        | 0.971             | 100 fg                    | Mice                         | This report                                                                  |
| Superoxide Dismutase B1 (SODB1)           | 1           | Sybr        | 0.91              | 50 parasites              | Mice                         | Ghotloo (2015)                                                               |